Hypera : Notice to the Market - New CH Head

HYPERA S.A.

A Publicly-Held Corporation

CNPJ/MF nº. 02.932.074/0001-91

NIRE 35.300.353.251

NOTICE TO THE MARKET

Hypera S.A. ("Company" or "Hypera Pharma") hereby informs the hiring of the executive Mr. Hélio Segouras as Head of the Consumer Health business unit, which counts on leading brands in its portfolio, such as Benegrip, Coristina d, Tamarine, Engov, Epocler, Doril, Estomazil, Gelol, Apracur, Biotônico Fontoura, Maracugina, Merthiolate, Polaramine and Vitasay.

This position was being temporarily held by Mr. Luiz Clavis, current Vice President of Marketing and Sales, who is responsible for the Company's three business units: Branded Prescription, Generics & Similars and Consumer Health.

The executive, who has a degree in Business Administration from the University of São Paulo (USP), has more than 20 years of experience in the pharmaceutical sector, having worked for multinational companies such as Novartis (2005 to 2018, where he held the position of Head of Specialties, focusing on Ophthalmology and Neuroscience), Pfizer Consumer Health (2000 to 2005) and P&G (1996 to 2000).

In 2017, Hypera Pharma ended the year as Brazil's largest advertiser, largely as a result of the media investment made to support the growing demand for brands from the Consumer Health business unit. According to IQVIA data for the period from July 2017 to June 2018, the Company is the leader in Consumer Health in Brazil.

São Paulo, September 10, 2018.

Hypera S.A.

Adalmario Ghovatto Satheler do Couto

Investor Relations Officer